Neurogene Says NGN-401 Gene Therapy For Rett Syndrome Has Been Selected To Participate In FDA Support For Clinical Trials Advancing Rare Disease Therapeutics Pilot Program
Neurogene Says NGN-401 Gene Therapy For Rett Syndrome Has Been Selected To Participate In FDA Support For Clinical Trials Advancing Rare Disease Therapeutics Pilot Program
Neurogene表示NGN-401基因療法用於Rett綜合症已被選中參與FDA支持的罕見疾病治療推進臨牀試驗計劃。
As part of the START Program, Neurogene will have opportunities for enhanced communications with the FDA, with the aim to further accelerate the pace of NGN-401's development. Two dose levels of NGN-401 are being evaluated in a Phase 1/2 clinical trial.
作爲開始控件計劃的一部分，Neurogene將有機會與FDA加強通信，旨在進一步加速NGN-401的開發速度。NGN-401的兩個劑量水平正在進行1/2期臨床試驗評估。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。